Gland Pharma IPO: Check Open/Close Date, IPO Price, IPO Size | Espresso


Gland Pharma IPO – Nov 9 to 11

November 05, 2020
Gland Pharma IPO – Nov 9 to 11

Gland Pharma Limited is coming out with a fresh public issue to raise Rs 6,480 crores from the market.

Key details of the issue:

  • Issue opens – Nov 9, 2020 (Monday)
  • Issue closes – Nov 11, 2020 (Wednesday)
  • Issue size – Rs 6,480 crores
  • Price band – Rs 1,490 – 1,500

Also Read: Know about Pre-IPO investing

And here are some details of the company and further details on the Gland Pharma Limited issue:

Company Details

Gland Pharma Limited is one of the fastest growing generic-injectables-focused companies by revenue in the United States from 2014 to 2019 (Source: IQVIA Report). Company sells its products primarily under a business to business (“B2B”) model in over 60 countries as of June 30, 2020, including the United States, Europe, Canada, Australia, India and the rest of the world.

Company has a consistent compliance track record with a range of regulatory regimes across these markets. Company also has an extensive track record in complex injectables development; manufacturing and marketing; and a close understanding of the related sophisticated scientific, technical and regulatory processes.

Company was established in Hyderabad, India, in 1978 and has expanded from liquid parenterals to cover other elements of the injectables value chain, including contract development, own development, dossier preparation and filing, technology transfer and manufacturing across a range of delivery systems.

Company is present in sterile injectables, oncology and ophthalmics, and focuses on complex injectables, NCE-1s, First-to-File products and 505(b)(2) filings. Company’s delivery systems include liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags and drops. Company is expanding its development and manufacturing capabilities in complex injectables such as peptides, long-acting injectables, suspensions and hormonal products as well as new delivery systems such as pens and cartridges.

Company has seven manufacturing facilities in India, comprising four finished formulations facilities with a total of 22 production lines and three API facilities. As of June 30, 2020, Company had manufacturing capacity for finished formulations of approximately 755 million units per annum.

Issue Size

Rs 6,480 crores

Issue Break-up

QIB – 50% of the offer – Rs 3,240 crores

NIB – 15% of the offer – Rs 972 crores

RET – 35% of the offer – Rs 2,268 crores




Link Intime India Private Limited


All retail applications through brokers are compulsorily in UPI mode

Team Espresso
by Team Espresso

We care that you succeed

Bringing readers the latest happenings from the world of Trading and Investments specifically and Finance in general.